Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abeona licenses REGENXBIO's NAV AAV9 vector for rare lysosomal storage diseases; Agreement Terminated/Cancelled

Executive Summary

Abeona Therapeutics Inc. licensed REGENXBIO Inc.'s adeno-associated virus vector NAV AAV9 to develop and commercialize in vivo gene therapies for four rare inherited lysosomal storage disorders (LSDs): Sanfilippo syndrome Type A (or mucopolysaccharidosis (MPS) IIIA), Sanfilippo syndrome Type B (MPS IIIB), neuronal ceroid lipofuscinosis Type 1 (CLN1, also known as infantile Batten disease), and CLN3 (also known as juvenile Batten disease).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies